<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430063</url>
  </required_header>
  <id_info>
    <org_study_id>R2810-ONC-1763</org_study_id>
    <secondary_id>2017-003684-35</secondary_id>
    <nct_id>NCT03430063</nct_id>
  </id_info>
  <brief_title>A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer</brief_title>
  <official_title>A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 &lt;50%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the objective response rate(ORR) of high
      dose REGN2810 (HDREGN2810) and standard dose REGN2810 plus ipilimumab combination therapy
      (SDREGN2810/ipi) versus standard dose REGN2810 (SDREGN2810) in the second-line treatment of
      patients with advanced or metastatic squamous or non-squamous non-small cell lung cancer
      (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in &lt;50% of
      tumor cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 16, 2018</start_date>
  <completion_date type="Anticipated">November 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 31 months</time_frame>
    <description>Proportion of patients achieving complete response (CR) or partial response (PR) as assessed by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading system</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs) as assessed by the NCI-CTCAE grading system</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities as assessed by the NCI-CTCAE grading system</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of immunogenicity as measured by anti-drug antibody (ADA) titers for REGN2810</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hair pigmentation</measure>
    <time_frame>Up to 31 months</time_frame>
    <description>As determined by investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor mutation burden as assessed by the Foundation Medicine &quot;FoundationOne®&quot; panel</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor volume</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inducible co-stimulatory positive (ICOS+) cluster of differentiation 4 (CD4) T-cell frequency and other markers of T-cell activation</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics(PK): Concentration at end of infusion (Ceoi)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Preinfusion concentration (Ctrough)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of end of infusion (teoi)</measure>
    <time_frame>Up to 31 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Metastatic Non-Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>SDREGN2810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SDREGN2810/ipi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HDREGN2810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDREGN2810</intervention_name>
    <description>Standard dose intravenous (IV) infusion</description>
    <arm_group_label>SDREGN2810</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDREGN2810/ipi</intervention_name>
    <description>Combination therapy dose IV</description>
    <arm_group_label>SDREGN2810/ipi</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>cemiplimab</other_name>
    <other_name>ipilimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDREGN2810</intervention_name>
    <description>High dose IV</description>
    <arm_group_label>HDREGN2810</arm_group_label>
    <other_name>REGN2810</other_name>
    <other_name>cemiplimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patients with histologically or cytologically documented squamous or non-squamous
             NSCLC who either have stage 3b disease and are not candidates for definitive
             concurrent chemo-radiation or have stage 4 disease. Patients must be immunotherapy
             naive and must have received one prior cytotoxic regimen.

          2. Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded
             tumor tissue biopsy sample

          3. Expression of PD-L1 in &lt;50% of tumor cells determined by a PD-L1 Immunohistochemistry
             (IHC) pharma diagnostic test (pharmDx) assay performed by a central laboratory

          4. At least 1 radiographically measureable lesion by computed tomography (CT) per RECIST
             1.1 criteria

          5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          6. Anticipated life expectancy of at least 3 months

        Key Exclusion Criteria:

          1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime

          2. Active or untreated brain metastases or spinal cord compression

          3. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene
             mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene
             receptor tyrosine kinase (ROS1) fusions

          4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed
             consent

          5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing
             pneumonia), or active, noninfectious pneumonitis that required immune-suppressive
             doses of glucocorticoids to assist with management, or of pneumonitis within the last
             5 years

          6. Ongoing or recent evidence of significant autoimmune disease that required treatment
             with systemic immunosuppressive treatments, which may suggest a risk of immunerelated
             treatment-emergent adverse events (irTEAEs)

          7. Patients with a condition requiring corticosteroid therapy (&gt;10 mg prednisone/day or
             equivalent) within 14 days of randomization

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Massillon</city>
        <state>Ohio</state>
        <zip>44646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced non-squamous NSCLC</keyword>
  <keyword>Advanced squamous NSCLC</keyword>
  <keyword>Metastatic non-squamous NSCLC</keyword>
  <keyword>Metastatic squamous NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

